TriangleDISEASE & TREATMENT SETTING
ADCETRIS: recurrent Mycosis Fungoides after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1.7 Relapsed Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) or CD30-Expressing Mycosis Fungoides (MF) ADCETRIS is indicated for the treatment of adult patients with pcALCL or CD30-expressing MF who have received prior systemic therapy.
Broader topic: Mycosis Fungoides
- Source population
- Not part of this definition
- Disease extent
- recurrent
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- who have received prior systemic therapy
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for ADCETRIS (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1.7 Relapsed Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) or CD30-Expressing Mycosis Fungoides (MF) ADCETRIS is indicated for the treatment of adult patients with pcALCL or CD30-expressing MF who have received prior systemic therapy.
Study evidence for this setting
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice